fbpx

Category

Lundbeckfonden Ventures
The U.S. Food and Drug Administration has granted 510(k) clearance for Asante Solutions' Pearl Insulin Pump. ASANTE_press_release_051711.pdf
DBV demonstrates ability of VIASKIN® to administer allergen via intact skin by targeting dendrictic cells for safe treatment of allergic disease. News_J_Immunol.pdf
Syntaxin enters manufacturing agreement with SynCo Bio Partners B.V. Progresses Acromegaly programme towards clinic. SynCo_Bio_Release_9_5_2011_(2).pdf
Funds to be used to complete two Phase II programmes
Nexstim, a medical device company, raises over EUR 11 million in new equity financing. Helsinki, Finland – January 26, 2011 – Nexstim Oy, a medical device company commercializing noninvasive brain diagnostic and therapy technologies, today announced that it has closed on additional equity financing of approximately EUR 11.4 million. The investment round was led by...
Russell G. Greig Appointed as Chairman of SyntaxinOxford, UK, 6th January 2011: Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, today announced Dr Russell G. Greig, Ph. D., has been appointed as Chairman with immediate effect. In joining Syntaxin, Dr. Greig brings with him over 30 years experience in the pharmaceutical industry,...
DBV Technologies closes $25.5 (?19,4) million Series ‘C’ financing round including new investors InnoBio, Lundbeckfond Ventures, Shire plc, and ALTO Invest; as well as existing investors Sofinnova Partners and ALK AbelloProceeds will be used, for the most part, to further continue the clinical development of VIASKIN® Peanut, the world’s first epicutaneous skin patch for desensitization...
1 53 54 55 56

Nyheder

A female dog may well be the answer
24. January 2020
Research project to investigate potential link between headache pills and early-stage spontaneous abortion
6. January 2020
Cancer patients donate living brain cells to scientists
17. December 2019

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge